158 related articles for article (PubMed ID: 28239612)
21. A novel clinically relevant graft-versus-leukemia model in humanized mice.
Jia B; Zhao C; Bayerl M; Shike H; Claxton DF; Ehmann WC; Mineishi S; Schell TD; Zheng P; Zhang Y; Shultz LD; Prabhu KS; Paulson RF; Zheng H
J Leukoc Biol; 2022 Feb; 111(2):427-437. PubMed ID: 34057741
[TBL] [Abstract][Full Text] [Related]
22. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML.
Pearce DJ; Taussig D; Zibara K; Smith LL; Ridler CM; Preudhomme C; Young BD; Rohatiner AZ; Lister TA; Bonnet D
Blood; 2006 Feb; 107(3):1166-73. PubMed ID: 16234360
[TBL] [Abstract][Full Text] [Related]
23. Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis.
Triviai I; Ziegler M; Bergholz U; Oler AJ; Stübig T; Prassolov V; Fehse B; Kozak CA; Kröger N; Stocking C
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8595-600. PubMed ID: 24912157
[TBL] [Abstract][Full Text] [Related]
24. Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival.
Monaco G; Konopleva M; Munsell M; Leysath C; Wang RY; Jackson CE; Korbling M; Estey E; Belmont J; Andreeff M
Stem Cells; 2004; 22(2):188-201. PubMed ID: 14990858
[TBL] [Abstract][Full Text] [Related]
25. Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.
Morad SAF; Davis TS; MacDougall MR; Tan SF; Feith DJ; Desai DH; Amin SG; Kester M; Loughran TP; Cabot MC
Biochem Pharmacol; 2017 Apr; 130():21-33. PubMed ID: 28189725
[TBL] [Abstract][Full Text] [Related]
26. Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.
Morad SA; Tan SF; Feith DJ; Kester M; Claxton DF; Loughran TP; Barth BM; Fox TE; Cabot MC
Biochim Biophys Acta; 2015 Jul; 1851(7):919-28. PubMed ID: 25769964
[TBL] [Abstract][Full Text] [Related]
27. inv(16) and NPM1mut AMLs engraft human cytokine knock-in mice.
Ellegast JM; Rauch PJ; Kovtonyuk LV; Müller R; Wagner U; Saito Y; Wildner-Verhey van Wijk N; Fritz C; Rafiei A; Lysenko V; Dudkiewicz E; Theocharides AP; Soldini D; Goede JS; Flavell RA; Manz MG
Blood; 2016 Oct; 128(17):2130-2134. PubMed ID: 27581357
[TBL] [Abstract][Full Text] [Related]
28. Evaluating Human Immune Responses for Vaccine Development in a Novel Human Spleen Cell-Engrafted NOD-SCID-IL2rγNull Mouse Model.
Ghosn S; Chamat S; Prieur E; Stephan A; Druilhe P; Bouharoun-Tayoun H
Front Immunol; 2018; 9():601. PubMed ID: 29628927
[TBL] [Abstract][Full Text] [Related]
29. Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.
Lewis AC; Pope VS; Tea MN; Li M; Nwosu GO; Nguyen TM; Wallington-Beddoe CT; Moretti PAB; Anderson D; Creek DJ; Costabile M; Ali SR; Thompson-Peach CAL; Dredge BK; Bert AG; Goodall GJ; Ekert PG; Brown AL; D'Andrea R; Robinson N; Pitman MR; Thomas D; Ross DM; Gliddon BL; Powell JA; Pitson SM
Blood; 2022 Jun; 139(26):3737-3751. PubMed ID: 35443029
[TBL] [Abstract][Full Text] [Related]
30. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.
Tavor S; Petit I; Porozov S; Avigdor A; Dar A; Leider-Trejo L; Shemtov N; Deutsch V; Naparstek E; Nagler A; Lapidot T
Cancer Res; 2004 Apr; 64(8):2817-24. PubMed ID: 15087398
[TBL] [Abstract][Full Text] [Related]
31. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.
Stroopinsky D; Rosenblatt J; Ito K; Mills H; Yin L; Rajabi H; Vasir B; Kufe T; Luptakova K; Arnason J; Nardella C; Levine JD; Joyce RM; Galinsky I; Reiter Y; Stone RM; Pandolfi PP; Kufe D; Avigan D
Cancer Res; 2013 Sep; 73(17):5569-79. PubMed ID: 23867470
[TBL] [Abstract][Full Text] [Related]
32. Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies.
Xia X; Li H; Satheesan S; Zhou J; Rossi JJ
J Vis Exp; 2019 Jan; (143):. PubMed ID: 30663638
[TBL] [Abstract][Full Text] [Related]
33. Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression.
Brehm MA; Kenney LL; Wiles MV; Low BE; Tisch RM; Burzenski L; Mueller C; Greiner DL; Shultz LD
FASEB J; 2019 Mar; 33(3):3137-3151. PubMed ID: 30383447
[TBL] [Abstract][Full Text] [Related]
34. The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice.
Culen M; Kosarova Z; Jeziskova I; Folta A; Chovancova J; Loja T; Tom N; Bystry V; Janeckova V; Dvorakova D; Mayer J; Racil Z
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1239-1251. PubMed ID: 29721667
[TBL] [Abstract][Full Text] [Related]
35. Combined IL-15 and IL-12 drives the generation of CD34
Cany J; van der Waart AB; Spanholtz J; Tordoir M; Jansen JH; van der Voort R; Schaap NM; Dolstra H
Oncoimmunology; 2015 Jul; 4(7):e1017701. PubMed ID: 26140247
[TBL] [Abstract][Full Text] [Related]
36. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
37. Enhanced development of functional human NK cells in NOD-scid-IL2rg
Aryee KE; Burzenski LM; Yao LC; Keck JG; Greiner DL; Shultz LD; Brehm MA
FASEB J; 2022 Sep; 36(9):e22476. PubMed ID: 35959876
[TBL] [Abstract][Full Text] [Related]
38. Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines.
Zhang Y; He L; Selimoglu-Buet D; Jego C; Morabito M; Willekens C; Diop MK; Gonin P; Lapierre V; Droin N; Solary E; Louache F
Blood Adv; 2017 Jun; 1(14):972-979. PubMed ID: 29296739
[TBL] [Abstract][Full Text] [Related]
39. Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models.
Carretta M; de Boer B; Jaques J; Antonelli A; Horton SJ; Yuan H; de Bruijn JD; Groen RWJ; Vellenga E; Schuringa JJ
Exp Hematol; 2017 Jul; 51():36-46. PubMed ID: 28456746
[TBL] [Abstract][Full Text] [Related]
40. Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.
Ung J; Tan SF; Fox TE; Shaw JJP; Vass LR; Costa-Pinheiro P; Garrett-Bakelman FE; Keng MK; Sharma A; Claxton DF; Levine RL; Tallman MS; Cabot MC; Kester M; Feith DJ; Loughran TP
Blood Rev; 2022 Sep; 55():100950. PubMed ID: 35487785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
